Integrated Diagnostics Holdings (LSE:IDHC) ROCE % : 12.34% (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Integrated Diagnostics Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Integrated Diagnostics Holdings's annualized ROCE % for the quarter that ended in Jun. 2023 was 12.34%.

Integrated Diagnostics Holdings ROCE % Historical Data

The historical data trend for Integrated Diagnostics Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrated Diagnostics Holdings ROCE % Chart

Integrated Diagnostics Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

30.29

34.42

66.03

19.67

18.90

Integrated Diagnostics Holdings Quarterly Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															4.65	22.96	22.34	12.34	-

Integrated Diagnostics Holdings ROCE % Calculation

Integrated Diagnostics Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	28.438	/	( ( (214.978 - 59.467)	+	(186.675 - 41.262) )	/ 2 )
	=	28.438	/	( (155.511	+	145.413)	/ 2 )
	=	28.438	/	150.462
	=	18.90 %

Integrated Diagnostics Holdings's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	16.708	/	( ( (180.791 - 44.525)	+	(177.08 - 42.576) )	/ 2 )
	=	16.708	/	( ( 136.266	+	134.504 )	/ 2 )
	=	16.708	/	135.385
	=	12.34 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

Integrated Diagnostics Holdings (LSE:IDHC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Integrated Diagnostics Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Integrated Diagnostics Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Integrated Diagnostics Holdings (LSE:IDHC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Integrated Diagnostics Holdings PLC (LSE:IDHC) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

IDGXF:USA IDHCl:UK IDHC.CA:Egypt 8I8:Germany

Address

12 Castle Street, Saint Helier, JEY, JE2 3RT

Website

https://www.idhcorp.com

Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider. It is a fully integrated diagnostics service provider operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segment- Contract Segment and Walk-in Segment. It derives majority of its revenue from services offered in Egypt.

Integrated Diagnostics Holdings (LSE:IDHC) Headlines

No Headlines